We are thrilled to announce that Dr. Steven Locke will be a distinguished speaker at the highly anticipated Psychedelic Science 2025 event, held in Denver, Colorado. Dr. Locke will contribute his expertise to a crucial session titled “Studying Psychedelics, Safety, and Risk,” a cornerstone discussion for the responsible advancement of psychedelic-assisted therapy.
This vital session will take place on Wednesday, June 18, from 12:15 PM – 1:00 PM MDT (2:15 PM – 3:00 PM EDT) in the STUDIES – Mile High Ballroom 1B. The panel will critically analyze adverse events reported across clinical trials of various psychedelic compounds and therapeutic uses. By examining the nature, frequency, and severity of these events, Dr. Locke and his fellow panelists will provide a clearer picture of the risk-benefit profile of this emerging treatment approach. Attendees will gain valuable insights into the lessons researchers must carry forward into future clinical research.
This session is eligible for CE and CME credits, offering a valuable opportunity for professionals to deepen their understanding of this rapidly evolving field. For more information on continuing education, please visit the Continuing Education Information Page.
Dr. Locke will be joined by experts from leading institutions, including the University of Colorado School of Medicine, UCSF Fresno, the Department of Medicine at the University of Fribourg, Switzerland, Wesley Ryan, MD, and Associates, and Columbia University Medical Center / New York State Psychiatric Institute. As a Psychiatrist from Harvard Medical School, Dr. Locke’s participation underscores the rigorous and thoughtful approach being taken to ensure the safe and effective integration of psychedelics into therapeutic practice.
A Leader in HPPD Treatment
Dr. Steven Locke, a Harvard- and Cornell-trained psychiatrist, is a nationally and internationally recognized expert in Hallucinogen Persisting Perception Disorder (HPPD) and Visual Snow Syndrome (VSS). He is one of the few specialists in the country with extensive knowledge of these rare conditions. Upon the retirement of Dr. Henry Abraham, the pioneering researcher who defined HPPD for the DSM, Dr. Locke assumed care for many of his patients, further solidifying his position at the forefront of HPPD treatment. With over 75 patients treated from national and international referrals, Dr. Locke’s private practice focuses on the comprehensive assessment and treatment of HPPD and related visual-perceptual disorders. His expertise includes medication management (such as lamotrigine and clonazepam), coaching, and Cognitive Behavioral Therapy (CBT). Dr. Locke is also a Primary Care Psychiatrist and Faculty member at Harvard Medical School, and has been recognized as a Boston Magazine “Top Doctor” from 2017 through 2025. He offers telehealth appointments nationwide, including in MA, NY, CA, FL, TN, and KS.
Join us at Psychedelic Science 2025 to learn from Dr. Locke and other leading voices as they explore the crucial aspects of psychedelic research, focusing on safety and risk to guide the future of this promising field.